CARL DEFRANCO: Open Payments
NPI 1033777867 · BUFFALO, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,533 in 120 payments from 15 companies in 2025. Trend: 2023 $7,999 · 2024 $13,731 · 2025 $4,533
Food & beverage: $2,463Speaker / faculty: $1,971Education: $100
| Company | Payments | Amount |
|---|---|---|
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 5 | $2,145 |
| Otsuka America Pharmaceutical, Inc. | 50 | $922 |
| E.R. Squibb & Sons, L.L.C. | 16 | $307 |
| Neurocrine BioSciences, Inc. | 8 | $273 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 15 | $208 |
| Alkermes, Inc. | 8 | $184 |
| MERZ NORTH AMERICA, INC. | 5 | $165 |
| Teva Pharmaceuticals USA, Inc. | 4 | $139 |
| Luye Pharma (USA) Ltd. | 3 | $59 |
| Biogen, Inc. | 1 | $27 |
Products named: ABILIFY ASIMTUFII, REXULTI, COBENFY, INGREZZA, CAPLYTA, ARISTADA, Xeomin, ABILIFY MAINTENA.
Industry payments across NY — which companies pay providers there.
